PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to assist employers,…
The Centers for Medicare and Medicaid (CMS) published on May 9, 2022, the highly anticipated Medicare Advantage and Part D Final Rule CMS-4192-F. The intention…
The engine that drives program optimization is integrated pharmacy and medical analytics. Monitoring data is vital and monitoring it across both medical and pharmacy is…
Today’s pharmacy benefit landscape can feel like a minefield of complex contracts, performance promises, intricate plan designs, and endless benefit considerations. Employers must trust in…
Overview Over 30% of plan sponsors are exploring alternate models driven mostly by high-cost specialty medications and the need to reduce inappropriate utilization. Right now,…
What is the point of negotiating stringent contract terms and conditions if no one ensures the rules are followed? Strategic vendor oversight is the independent…
What is cystic fibrosis? People tend to consider cystic fibrosis (CF) a pediatric disease; however, it can also affect adults. CF is an autosomal recessive…
Implementation of best-in-class PBM contracting The negotiation process starts with the bid. A well-managed procurement sets the expectation that the bidding PBMs will adhere to…
Pharmaceutical Strategies Group (PSG) is pleased to present the 2022 Trends in Drug Benefit Design Report, which details traditional (non-specialty) drug benefit trends and…
On January 10, 2022, guidance was released requiring group health plans and insurers to cover over-the-counter (OTC) COVID-19 diagnostic tests for members without cost sharing…
Utilization management (UM) programs are a vital tool in the clinical and cost management of drugs. These programs are offered in various forms by most…
